These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol. Merat S; Poustchi H; Hemming K; Jafari E; Radmard AR; Nateghi A; Shiravi Khuzani A; Khoshnia M; Marshall T; Malekzadeh R Arch Iran Med; 2015 Aug; 18(8):515-23. PubMed ID: 26265520 [TBL] [Abstract][Full Text] [Related]
6. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A; Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715 [TBL] [Abstract][Full Text] [Related]
7. Polypill with or without Aspirin in Persons without Cardiovascular Disease. Yusuf S; Joseph P; Dans A; Gao P; Teo K; Xavier D; López-Jaramillo P; Yusoff K; Santoso A; Gamra H; Talukder S; Christou C; Girish P; Yeates K; Xavier F; Dagenais G; Rocha C; McCready T; Tyrwhitt J; Bosch J; Pais P; N Engl J Med; 2021 Jan; 384(3):216-228. PubMed ID: 33186492 [TBL] [Abstract][Full Text] [Related]
8. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Soliman EZ; Mendis S; Dissanayake WP; Somasundaram NP; Gunaratne PS; Jayasingne IK; Furberg CD Trials; 2011 Jan; 12():3. PubMed ID: 21205325 [TBL] [Abstract][Full Text] [Related]
9. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A; Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727 [TBL] [Abstract][Full Text] [Related]
10. Polypill for Cardiovascular Disease Prevention in an Underserved Population. Muñoz D; Uzoije P; Reynolds C; Miller R; Walkley D; Pappalardo S; Tousey P; Munro H; Gonzales H; Song W; White C; Blot WJ; Wang TJ N Engl J Med; 2019 Sep; 381(12):1114-1123. PubMed ID: 31532959 [TBL] [Abstract][Full Text] [Related]
11. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. Carey KM; Comee MR; Donovan JL; Kanaan AO Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437 [TBL] [Abstract][Full Text] [Related]
12. The evening versus morning polypill utilization study: the TEMPUS rationale and design. Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539 [TBL] [Abstract][Full Text] [Related]
13. The concept of the polypill in the prevention of cardiovascular disease. Wiley B; Fuster V Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562 [TBL] [Abstract][Full Text] [Related]
14. Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention. Marzal D; Rodríguez Padial L; Arnáiz JA; Castro A; Cosín J; Lekuona I; Guijarro C Clin Investig Arterioscler; 2018; 30(5):240-247. PubMed ID: 30017176 [TBL] [Abstract][Full Text] [Related]
15. Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients. Ros-Castelló V; Natera-Villalba E; Gómez-López A; Sánchez-Sánchez A; Chico-García JL; García-Madrona S; Vera-Lechuga R; Matute-Lozano C; de Felipe Mimbrera A; Cruz-Culebras A; Alonso-Canovas A; Masjuan J Cerebrovasc Dis Extra; 2020; 10(3):166-173. PubMed ID: 33176324 [TBL] [Abstract][Full Text] [Related]
16. Fixed Dose Combination Therapy for Secondary Prevention of Major Cardiovascular Events: Review of Literature and Design for Persian Polypill, A Randomized Clinical Trial. Sadeghi M; Hoseini SG; Nateghi A; Sarrafzadegan N; Mansoorian M; Najafian J; Roohafza H Curr Probl Cardiol; 2022 Jun; 47(6):100872. PubMed ID: 34016484 [TBL] [Abstract][Full Text] [Related]
17. Improving cardiovascular protection: focus on a cardiovascular polypill. Barrios V; Escobar C Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213 [TBL] [Abstract][Full Text] [Related]
18. Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial. Merat S; Jafari E; Radmard AR; Khoshnia M; Sharafkhah M; Nateghi Baygi A; Marshall T; Shiravi Khuzani A; Cheng KK; Poustchi H; Malekzadeh R Eur Heart J; 2022 Jun; 43(21):2023-2033. PubMed ID: 35048107 [TBL] [Abstract][Full Text] [Related]
19. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. Lafeber M; Spiering W; van der Graaf Y; Nathoe H; Bots ML; Grobbee DE; Visseren FL Am Heart J; 2013 Aug; 166(2):282-289.e1. PubMed ID: 23895811 [TBL] [Abstract][Full Text] [Related]
20. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease. Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A; Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]